Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361232 | 0.82 | — | — | |
| SCHEMBL251357 | 0.71 | MGMT (0.40) | MMP1MMP2MMP9MMP12ATM | |
| SCHEMBL4082360 | 0.71 | FBP1 (0.39) | MMP1MMP2MMP9MMP12ATM | |
| SCHEMBL9682640 | 0.69 | MGMT (0.39) | MMP1MMP2MMP9MMP12ATM | |
| SCHEMBL2393419 | 0.68 | — | — | |
| SCHEMBL181927 | 0.67 | — | — | |
| SCHEMBL247102 | 0.67 | — | — | |
| SCHEMBL266567 | 0.67 | — | — | |
| SCHEMBL2404075 | 0.67 | — | — | |
| SCHEMBL73652 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115989033-A | Compositions and methods for TCR reprogramming using CD 70-specific fusion proteins | T细胞受体治疗公司 | 2023-04-18 | — | — | CN | claimed |
| CN-111902148-B | Compositions and methods for treating muscular atrophy and tonic muscular dystrophy | 艾维迪提生物科学公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118267396-A | Nucleic acid-polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118265544-A | Compositions and methods for treating facial shoulder brachial muscular dystrophy | 艾维迪提生物科学公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-111655268-B | Nucleic acid-polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117615790-A | FN3 domain-siRNA conjugates and uses thereof | ARO生物疗法公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117597112-A | Extracellular vesicles loaded with biomolecules | 鉴识生物系统有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-109715805-B | Nucleic acid-polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-116171163-A | Therapeutic extracellular vesicles | 俄亥俄州国家创新基金会 | 2023-05-26 | — | — | CN | disclosed |
| CN-115989033-A | Compositions and methods for TCR reprogramming using CD 70-specific fusion proteins | T细胞受体治疗公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-1185692-B1 | MONOLAYER AND ELECTRODE FOR DETECTING A LABEL-BEARING TARGET AND METHOD OF USE THEREOF | UNIV NORTH CAROLINA (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-6387625-B1 | ELECTRODE HAVING SUBSTRATE WITH ELECTROCONDUCTIVE WORKING SURFACE; SURFACE HAS NONCONDUCTIVE SELF-ASSEMBLED MONOLAYER WITH PHOSPHONATE GROUP; A TRANSITION METAL COMPLEX IS USED TO TRANSFER ELECTRONS FROM REACTANT TO SURFACE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2002-05-14 | — | — | US | disclosed |
| EP-1185692-A1 | MONOLAYER AND ELECTRODE FOR DETECTING A LABEL-BEARING TARGET AND METHOD OF USE THEREOF | The University of North Carolina at Chapel Hill (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000065099-A1 | MONOLAYER AND ELECTRODE FOR DETECTING A LABEL-BEARING TARGET AND METHOD OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-11-02 | — | — | WO | disclosed |
| US-6127127-A | Monolayer and electrode for detecting a label-bearing target and method of use thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | MMP1 1032/4885MMP2 734/4885MMP9 1128/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | MMP1 3502/4885MMP2 1716/4885MMP9 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.